Lyell Immunopharma secures $80 million private placement to fund CAR‑T trials
+2 new sources since this summary was written
Lyell Immunopharma entered a securities purchase agreement to sell roughly 7.4 million common shares, raising about $80 million. The financing, backed by investors such as ARCH Venture Partners, Adage Capital, Caligan Partners and RTW Investments, is expected to extend the company’s cash runway into 2028. The proceeds will support pivotal data generation for ronde‑cel and the regulatory filing of a Biologics License Application in the second half of 2027, as well as development of its LYL273 program. The transaction is slated to close on November 4, 2026.
Why it matters
The company says the cash will be sufficient to meet working‑capital and capital‑expenditure needs through 2028, covering key clinical milestones and the anticipated BLA submission. Extending the runway reduces immediate financing risk for investors.
Key facts
- 1Lyell agreed to sell 7,428,040 shares of common stock in the private placement. stocktitan.net
- 2The price per share is $10.77. tradingview.com
- 3The total amount to be raised is approximately $80 million. stocktitan.net
- 4Proceeds are expected to extend cash runway into 2028. stocktitan.net
- 5Investors participating include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP and RTW Investments. stocktitan.net
- 6Closing of the financing is anticipated on November 4, 2026. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.